董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James B. Frakes | 男 | Chief Executive Officer, Chief Financial Officer and Director | 69 | 82.69万美元 | 0.0063 | 2026-08-28 |
| Edward G. Broenniman | 男 | Chairman of the Board and Director | 89 | 14.75万美元 | 0.23 | 2026-08-28 |
| Chetan S. Shah | 男 | Director | 57 | 11.38万美元 | 0.20 | 2026-08-28 |
| Nicolas Gikakis | 男 | Director | 60 | 9.88万美元 | 0.20 | 2026-08-28 |
| Angela Rossetti | 女 | Director | 73 | 11.30万美元 | 0.27 | 2026-08-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James B. Frakes | 男 | Chief Executive Officer, Chief Financial Officer and Director | 69 | 82.69万美元 | 0.0063 | 2026-08-28 |
| Steven P. LaRosa | 男 | Chief Medical Officer | 59 | 59.35万美元 | 0.0057 | 2026-08-28 |
董事简历
中英对照 | 中文 | 英文- James B. Frakes
-
James B. Frakes，他于2008年1月加入Aethlon Medical公司，并带来了16年的上市公司财务经验，以及特定领域的知识和经验，涉及股票和债券交易、收购、公开报道和《萨班斯-奥克斯利法案》第404节内部控制要求。他也担任Exosome Sciences公司的首席财务官。他此前曾担任Left Behind Games公司（一家初创游戏公司）的首席财务官。2006年之前，他曾担任NTN Buzztime公司（一个互动娱乐公司）的首席财务官。他持有the University of Southern California的工商管理硕士学位，以及Stanford University的荣誉学士学位。
James B. Frakes has served as the Company's Chief Executive Officer and Chief Financial Officer since October 3, 2024, after serving as Interim Chief Executive Officer beginning in November 2023. He has been a director of the Company since November 2023 and Chief Financial Officer since September 2010. From January 2008 to September 2010, he served as the Company's Senior Vice President, Finance. Prior to joining the Company, Mr. Frakes was Chief Financial Officer for Left Behind Games Inc., a video game company, and previously served as Chief Financial Officer of NTN Buzztime, Inc., an interactive entertainment company. Mr. Frakes earned an MBA from the University of Southern California and a B.A. with Honors from Stanford University. - James B. Frakes，他于2008年1月加入Aethlon Medical公司，并带来了16年的上市公司财务经验，以及特定领域的知识和经验，涉及股票和债券交易、收购、公开报道和《萨班斯-奥克斯利法案》第404节内部控制要求。他也担任Exosome Sciences公司的首席财务官。他此前曾担任Left Behind Games公司（一家初创游戏公司）的首席财务官。2006年之前，他曾担任NTN Buzztime公司（一个互动娱乐公司）的首席财务官。他持有the University of Southern California的工商管理硕士学位，以及Stanford University的荣誉学士学位。
- James B. Frakes has served as the Company's Chief Executive Officer and Chief Financial Officer since October 3, 2024, after serving as Interim Chief Executive Officer beginning in November 2023. He has been a director of the Company since November 2023 and Chief Financial Officer since September 2010. From January 2008 to September 2010, he served as the Company's Senior Vice President, Finance. Prior to joining the Company, Mr. Frakes was Chief Financial Officer for Left Behind Games Inc., a video game company, and previously served as Chief Financial Officer of NTN Buzztime, Inc., an interactive entertainment company. Mr. Frakes earned an MBA from the University of Southern California and a B.A. with Honors from Stanford University.
- Edward G. Broenniman
-
Edward G. Broenniman，他于1999年3月成为Aethlon Medical公司的董事。他一直担任The Piedmont Group公司（投资咨询公司）的董事总经理（1978年以来）。他最近曾任职于QuesTech公司（上市公司，被CACI International公司收购）的董事会，目前任职于两家私人公司的董事会。他曾任职非营利性机构董事会，包括马里兰大学（the University of Maryland）的Dingman创业中心的顾问委员会、the National Association of Corporate Directors, National Capital Chapter、the Association for Corporate Growth, National Capital Chapter的董事会。
Edward G. Broenniman has served as a director of the Company since March 1999. He has been the Managing Director of The Piedmont Group, LLC, a venture advisory firm, since 1978. Mr. Broenniman currently serves on the boards of two privately held companies. He previously served on the boards of several nonprofit organizations, including the Dingman Center for Entrepreneurship Board of Advisors at the University of Maryland from 1989 to 2020, the National Capital Chapter of Corporate Directors, where he was Founder, Chair from 2003 to 2005 and director from 2001 to 2018 and the Association for Corporate Growth, National Capital Chapter, where he was Founder, Chair from 2000 to 2018. Mr. Broenniman earned an MBA from Stanford Graduate School of Business and his B.A. from Yale University. - Edward G. Broenniman，他于1999年3月成为Aethlon Medical公司的董事。他一直担任The Piedmont Group公司（投资咨询公司）的董事总经理（1978年以来）。他最近曾任职于QuesTech公司（上市公司，被CACI International公司收购）的董事会，目前任职于两家私人公司的董事会。他曾任职非营利性机构董事会，包括马里兰大学（the University of Maryland）的Dingman创业中心的顾问委员会、the National Association of Corporate Directors, National Capital Chapter、the Association for Corporate Growth, National Capital Chapter的董事会。
- Edward G. Broenniman has served as a director of the Company since March 1999. He has been the Managing Director of The Piedmont Group, LLC, a venture advisory firm, since 1978. Mr. Broenniman currently serves on the boards of two privately held companies. He previously served on the boards of several nonprofit organizations, including the Dingman Center for Entrepreneurship Board of Advisors at the University of Maryland from 1989 to 2020, the National Capital Chapter of Corporate Directors, where he was Founder, Chair from 2003 to 2005 and director from 2001 to 2018 and the Association for Corporate Growth, National Capital Chapter, where he was Founder, Chair from 2000 to 2018. Mr. Broenniman earned an MBA from Stanford Graduate School of Business and his B.A. from Yale University.
- Chetan S. Shah
-
Chetan S. Shah，自2013年6月起担任公司董事。Shah博士是一名董事会认证的耳鼻喉科医生。他是汉密尔顿外科中心的合伙人和董事会成员，也是他于2009年创立的Physician Management Systems和Princeton Eye & Ear。沙阿博士在另一家私营公司的董事会任职。他担任教学职务，在该地区的多个医院委员会任职，并在新泽西州的听力学和言语语言病理学委员会任职。沙阿博士也是新泽西州体检委员会的成员。Shah博士分别在罗格斯大学和罗伯特·伍德·约翰逊医学院获得学士学位和医学学位。
Chetan S. Shah has served as a director of the Company since June 2013. Dr. Shah is a board certified Otolaryngologist and is a partner and board member of the Surgery Center at Hamilton, Physician Management Systems and Princeton Eye & Ear, which he founded in 2009. He also serves on the board of directors of another private company. Dr. Shah holds teaching positions, serves on multiple hospital committees and serves on the Audiology and Speech Language Pathology Committee for the State of New Jersey. He previously served as member of the Board of Medical Examiners for the State of New Jersey. Dr. Shah received his bachelor's degree and medical degree from Rutgers University and Robert Wood Johnson Medical School, respectively. - Chetan S. Shah，自2013年6月起担任公司董事。Shah博士是一名董事会认证的耳鼻喉科医生。他是汉密尔顿外科中心的合伙人和董事会成员，也是他于2009年创立的Physician Management Systems和Princeton Eye & Ear。沙阿博士在另一家私营公司的董事会任职。他担任教学职务，在该地区的多个医院委员会任职，并在新泽西州的听力学和言语语言病理学委员会任职。沙阿博士也是新泽西州体检委员会的成员。Shah博士分别在罗格斯大学和罗伯特·伍德·约翰逊医学院获得学士学位和医学学位。
- Chetan S. Shah has served as a director of the Company since June 2013. Dr. Shah is a board certified Otolaryngologist and is a partner and board member of the Surgery Center at Hamilton, Physician Management Systems and Princeton Eye & Ear, which he founded in 2009. He also serves on the board of directors of another private company. Dr. Shah holds teaching positions, serves on multiple hospital committees and serves on the Audiology and Speech Language Pathology Committee for the State of New Jersey. He previously served as member of the Board of Medical Examiners for the State of New Jersey. Dr. Shah received his bachelor's degree and medical degree from Rutgers University and Robert Wood Johnson Medical School, respectively.
- Nicolas Gikakis
-
Nicolas Gikakis，自2013年6月起担任公司董事。Shah博士是一名董事会认证的耳鼻喉科医生。他是汉密尔顿外科中心的合伙人和董事会成员，也是他在2009年创立的医生管理系统和普林斯顿眼与耳中心的成员。沙阿博士是另一家私营公司的董事会成员。他担任教职，在该地区的多个医院委员会任职，并且是新泽西州听力学和言语语言病理学委员会的成员。Shah博士也是新泽西州体检委员会的成员。Shah博士在罗格斯大学和罗伯特·伍德·约翰逊医学院获得学士学位和医学学位。
Nicolas Gikakis has served as a director of the Company since July 2023. From 2021 to May 2023, Mr. Gikakis served Head of Commercial for WearOptimo Pty Ltd, a private Australian medical device and digital health company. From 2017 to 2019, he served as Vice President of Strategy and Corporate Development at Oventus Medical Limited, where he supported the commercial expansion of the company's sleep apnea device platform. From 2012 to 2021, Mr. Gikakis has held various leadership and independent strategic advisor positions in the healthcare industry focused on sales, marketing, product development, and corporate development, including for companies working with blood filtration and purification technologies. Mr. Gikakis holds a B.S. in Bioengineering from the University of Pennsylvania and an MBA from George Mason University. Earlier in his career, he worked in bench and clinical research, and gained clinical experience at the University of Pennsylvania. - Nicolas Gikakis，自2013年6月起担任公司董事。Shah博士是一名董事会认证的耳鼻喉科医生。他是汉密尔顿外科中心的合伙人和董事会成员，也是他在2009年创立的医生管理系统和普林斯顿眼与耳中心的成员。沙阿博士是另一家私营公司的董事会成员。他担任教职，在该地区的多个医院委员会任职，并且是新泽西州听力学和言语语言病理学委员会的成员。Shah博士也是新泽西州体检委员会的成员。Shah博士在罗格斯大学和罗伯特·伍德·约翰逊医学院获得学士学位和医学学位。
- Nicolas Gikakis has served as a director of the Company since July 2023. From 2021 to May 2023, Mr. Gikakis served Head of Commercial for WearOptimo Pty Ltd, a private Australian medical device and digital health company. From 2017 to 2019, he served as Vice President of Strategy and Corporate Development at Oventus Medical Limited, where he supported the commercial expansion of the company's sleep apnea device platform. From 2012 to 2021, Mr. Gikakis has held various leadership and independent strategic advisor positions in the healthcare industry focused on sales, marketing, product development, and corporate development, including for companies working with blood filtration and purification technologies. Mr. Gikakis holds a B.S. in Bioengineering from the University of Pennsylvania and an MBA from George Mason University. Earlier in his career, he worked in bench and clinical research, and gained clinical experience at the University of Pennsylvania.
- Angela Rossetti
-
Angela Rossetti，2013年6月起担任董事。2009年至2012年1月，她是Pfizer的副总裁，领导着戒烟专营的商业医药团队。2007年起，她担任Wyeth的助理副总裁，管理全球性的血友病专营药，直到2009年它被Pfizer收购。2005-2006，她担任Ogilvy Healthworld的总裁，这是制药与生物技术领域的广告公司。之前，她在传播、营销和风投/投行等方面，担任过愈益重要的多个职务。她不久前刚毕业于Albert Einstein College of Medicine，获得生物伦理硕士学位，并获得了Columbia University Graduate School of Business金融方向的工商管理硕士学位、University of Pennsylvania的生物学学士学位。
Angela Rossetti has served as a director of the Company since April 2022. Since March 2018, Dr. Rossetti has served as an independent consultant to companies in the biotechnology and pharmaceutical industries, including Kala Pharmaceuticals, Inc. and Celgene Corporation. From June 2015 through July 2017, Dr. Rossetti served as Vice President of Cell Machines, Inc., an early stage biopharmaceutical company developing novel protein therapies, where she supported commercialization activities for therapies targeting hemophilia and other diseases. Dr. Rossetti has held various positions within pharmaceutical commercial development, marketing, communications and finance, including serving as Vice President of a Global Commercial Medicine Team at Pfizer Inc. from 2007 to 2012, where she led a global smoking cessation initiative. Dr. Rossetti previously served on the board of directors of Palatin Technologies, Inc., a public biopharmaceutical company, from June 2013 to December 2020. Dr. Rossetti currently serves as an adjunct Assistant Professor of Medical and Pharmaceutical Ethics at New York Medical College and as an Adjunct Associate at Albert Einstein College of Medicine. Dr. Rossetti holds a Doctorate in Bioethics from Loyola University Chicago, where her studies focused on research ethics and rare disease ethics, an M.B.E from Montefiore Einstein, and an M.B.A. from Columbia University and a B.A. in Biology and English from the University of Pennsylvania. - Angela Rossetti，2013年6月起担任董事。2009年至2012年1月，她是Pfizer的副总裁，领导着戒烟专营的商业医药团队。2007年起，她担任Wyeth的助理副总裁，管理全球性的血友病专营药，直到2009年它被Pfizer收购。2005-2006，她担任Ogilvy Healthworld的总裁，这是制药与生物技术领域的广告公司。之前，她在传播、营销和风投/投行等方面，担任过愈益重要的多个职务。她不久前刚毕业于Albert Einstein College of Medicine，获得生物伦理硕士学位，并获得了Columbia University Graduate School of Business金融方向的工商管理硕士学位、University of Pennsylvania的生物学学士学位。
- Angela Rossetti has served as a director of the Company since April 2022. Since March 2018, Dr. Rossetti has served as an independent consultant to companies in the biotechnology and pharmaceutical industries, including Kala Pharmaceuticals, Inc. and Celgene Corporation. From June 2015 through July 2017, Dr. Rossetti served as Vice President of Cell Machines, Inc., an early stage biopharmaceutical company developing novel protein therapies, where she supported commercialization activities for therapies targeting hemophilia and other diseases. Dr. Rossetti has held various positions within pharmaceutical commercial development, marketing, communications and finance, including serving as Vice President of a Global Commercial Medicine Team at Pfizer Inc. from 2007 to 2012, where she led a global smoking cessation initiative. Dr. Rossetti previously served on the board of directors of Palatin Technologies, Inc., a public biopharmaceutical company, from June 2013 to December 2020. Dr. Rossetti currently serves as an adjunct Assistant Professor of Medical and Pharmaceutical Ethics at New York Medical College and as an Adjunct Associate at Albert Einstein College of Medicine. Dr. Rossetti holds a Doctorate in Bioethics from Loyola University Chicago, where her studies focused on research ethics and rare disease ethics, an M.B.E from Montefiore Einstein, and an M.B.A. from Columbia University and a B.A. in Biology and English from the University of Pennsylvania.
高管简历
中英对照 | 中文 | 英文- James B. Frakes
James B. Frakes，他于2008年1月加入Aethlon Medical公司，并带来了16年的上市公司财务经验，以及特定领域的知识和经验，涉及股票和债券交易、收购、公开报道和《萨班斯-奥克斯利法案》第404节内部控制要求。他也担任Exosome Sciences公司的首席财务官。他此前曾担任Left Behind Games公司（一家初创游戏公司）的首席财务官。2006年之前，他曾担任NTN Buzztime公司（一个互动娱乐公司）的首席财务官。他持有the University of Southern California的工商管理硕士学位，以及Stanford University的荣誉学士学位。
James B. Frakes has served as the Company's Chief Executive Officer and Chief Financial Officer since October 3, 2024, after serving as Interim Chief Executive Officer beginning in November 2023. He has been a director of the Company since November 2023 and Chief Financial Officer since September 2010. From January 2008 to September 2010, he served as the Company's Senior Vice President, Finance. Prior to joining the Company, Mr. Frakes was Chief Financial Officer for Left Behind Games Inc., a video game company, and previously served as Chief Financial Officer of NTN Buzztime, Inc., an interactive entertainment company. Mr. Frakes earned an MBA from the University of Southern California and a B.A. with Honors from Stanford University.- James B. Frakes，他于2008年1月加入Aethlon Medical公司，并带来了16年的上市公司财务经验，以及特定领域的知识和经验，涉及股票和债券交易、收购、公开报道和《萨班斯-奥克斯利法案》第404节内部控制要求。他也担任Exosome Sciences公司的首席财务官。他此前曾担任Left Behind Games公司（一家初创游戏公司）的首席财务官。2006年之前，他曾担任NTN Buzztime公司（一个互动娱乐公司）的首席财务官。他持有the University of Southern California的工商管理硕士学位，以及Stanford University的荣誉学士学位。
- James B. Frakes has served as the Company's Chief Executive Officer and Chief Financial Officer since October 3, 2024, after serving as Interim Chief Executive Officer beginning in November 2023. He has been a director of the Company since November 2023 and Chief Financial Officer since September 2010. From January 2008 to September 2010, he served as the Company's Senior Vice President, Finance. Prior to joining the Company, Mr. Frakes was Chief Financial Officer for Left Behind Games Inc., a video game company, and previously served as Chief Financial Officer of NTN Buzztime, Inc., an interactive entertainment company. Mr. Frakes earned an MBA from the University of Southern California and a B.A. with Honors from Stanford University.
- Steven P. LaRosa
Steven P.LaRosa自2021年1月起担任我们的首席医疗官，自2021年3月起担任代理首席科学官。LaRosa博士拥有超过20年的执业医师和传染病专家的经验。在加入Aethlon之前，Larosa博士担任Entasis Therapeutics临床开发副总裁，Entasis Therapeutics是阿斯利康的衍生产品，专注于病原体靶向小分子治疗严重的多重耐药革兰氏阴性感染。在加入Entasis之前，LaRosa博士是马萨诸塞州Beth Israel Beverly医院感染科的主治医师。拉罗萨博士仍然是贝弗利医院（Beverly Hospital，Beth Israel）抗微生物管理项目的医学主任。在加入Beth Israel之前，他是罗德岛医院感染科的主治医师。在此之前，LaRosa博士是克利夫兰诊所基金会感染科的助理医师。他也曾担任礼来公司的临床研究医师。在他的整个职业生涯中，拉罗萨博士有过几次学术任命。拉罗萨博士拥有波士顿大学医学院的医学博士学位和波士顿学院的生物学学士学位，并在克利夫兰诊所接受了五年的培训，包括首席住院医师的职位，以及在哈佛大学四年的职业发展。
Steven P. LaRosa has served as Chief Medical Officer since January 2021 and served as Chief Scientific Officer from May 2021 until February 2023. Prior to joining the Company, Dr. LaRosa served as the Vice President of Clinical Development of Entasis Therapeutics, a spin out of AstraZeneca focused on pathogen targeted small molecules to treat serious multidrug resistant Gram negative infections, from March 2020 to December 2020. Prior to joining Entasis, Dr. LaRosa served as an Attending Physician in the Division of Infectious Disease at Beverly Hospital, a member of Beth Israel Lahey Health. From September 2012 to March 2020, Dr. LaRosa served as an Attending Physician in the Division of Infectious Diseases at Rhode Island Hospital. Prior to that, he served as an Associate Staff Physician in the Department of Infectious Disease at the Cleveland Clinic Foundation and as Clinical Research Physician for Eli Lilly and Company. Throughout his career, Dr. LaRosa has had several academic appointments. Dr. LaRosa received his M.D. from Boston University School of Medicine and his B.S. in Biology from Boston College. He completed an Internal Medicine Residency and Chief Residency at the Cleveland Clinic Foundation and Infectious Disease Fellowship at Massachusetts General Hospital. He is Board Certified in Internal Medicine and Infectious Disease by the American Board of Internal Medicine.- Steven P.LaRosa自2021年1月起担任我们的首席医疗官，自2021年3月起担任代理首席科学官。LaRosa博士拥有超过20年的执业医师和传染病专家的经验。在加入Aethlon之前，Larosa博士担任Entasis Therapeutics临床开发副总裁，Entasis Therapeutics是阿斯利康的衍生产品，专注于病原体靶向小分子治疗严重的多重耐药革兰氏阴性感染。在加入Entasis之前，LaRosa博士是马萨诸塞州Beth Israel Beverly医院感染科的主治医师。拉罗萨博士仍然是贝弗利医院（Beverly Hospital，Beth Israel）抗微生物管理项目的医学主任。在加入Beth Israel之前，他是罗德岛医院感染科的主治医师。在此之前，LaRosa博士是克利夫兰诊所基金会感染科的助理医师。他也曾担任礼来公司的临床研究医师。在他的整个职业生涯中，拉罗萨博士有过几次学术任命。拉罗萨博士拥有波士顿大学医学院的医学博士学位和波士顿学院的生物学学士学位，并在克利夫兰诊所接受了五年的培训，包括首席住院医师的职位，以及在哈佛大学四年的职业发展。
- Steven P. LaRosa has served as Chief Medical Officer since January 2021 and served as Chief Scientific Officer from May 2021 until February 2023. Prior to joining the Company, Dr. LaRosa served as the Vice President of Clinical Development of Entasis Therapeutics, a spin out of AstraZeneca focused on pathogen targeted small molecules to treat serious multidrug resistant Gram negative infections, from March 2020 to December 2020. Prior to joining Entasis, Dr. LaRosa served as an Attending Physician in the Division of Infectious Disease at Beverly Hospital, a member of Beth Israel Lahey Health. From September 2012 to March 2020, Dr. LaRosa served as an Attending Physician in the Division of Infectious Diseases at Rhode Island Hospital. Prior to that, he served as an Associate Staff Physician in the Department of Infectious Disease at the Cleveland Clinic Foundation and as Clinical Research Physician for Eli Lilly and Company. Throughout his career, Dr. LaRosa has had several academic appointments. Dr. LaRosa received his M.D. from Boston University School of Medicine and his B.S. in Biology from Boston College. He completed an Internal Medicine Residency and Chief Residency at the Cleveland Clinic Foundation and Infectious Disease Fellowship at Massachusetts General Hospital. He is Board Certified in Internal Medicine and Infectious Disease by the American Board of Internal Medicine.